Haleos Labs Limited has successfully concluded its postal ballot process for seeking shareholder approval on Material Related Party Transactions involving the issuance of a corporate guarantee to RBL Bank. The resolution was passed on April 29, 2026, securing the External Corporate Borrowings facility availed by Mahi Drugs Private Limited, a subsidiary of the company.

Overwhelming Shareholder Support

The postal ballot results demonstrated exceptional shareholder confidence in the proposed transaction. The voting process was conducted exclusively through e-voting from March 31, 2026, to April 29, 2026, with Mr. C. Sudhir Babu of CSB Associates serving as the scrutinizer.

Category-wise Voting Breakdown

The detailed voting analysis reveals strong support across all shareholder categories. Public institutions showed unanimous support, while public non-institutions demonstrated near-complete approval for the resolution.

Resolution and Transaction Details

The Ordinary Resolution sought approval for the issuance of a corporate guarantee in favour of RBL Bank to secure the External Corporate Borrowings facility availed by Mahi Drugs Private Limited. Members holding equity shares as of the cut-off date of March 27, 2026, were entitled to vote on the proposed resolution. The Promoter and Promoter Group were interested parties in this agenda resolution.

Scrutinizer's Confirmation

Mr. C. Sudhir Babu, Practicing Company Secretary from CSB Associates, confirmed that the e-voting process was conducted in a fair and transparent manner. The company appointed Central Depository Services Limited (CDSL) as the agency for providing the e-voting facility. According to the scrutinizer's report, 68 members voted in favour while 3 members voted against the resolution, with no invalid votes recorded during the process.

Regulatory Compliance

The company has fulfilled all regulatory requirements under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The results have been uploaded on the company's website at www.haleoslabs.com and on Central Depository Services (India) Limited's website at www.cdslindia.com . The scrutinizer's report has been submitted to the Managing Director, and all relevant records relating to e-voting will remain in safe custody until the minutes are signed and approved.

Haleos Labs Limited has submitted its annual disclosure to stock exchanges confirming that no promoter shares were encumbered during the financial year 2025-26. The pharmaceutical company, formerly known as SMS Lifesciences India Limited, filed the mandatory disclosure under Regulation 31 of SEBI (SAST) Regulations on April 8, 2026.

Clean Shareholding Structure Maintained

The disclosure, signed by Mr. TVVSN Murthy on behalf of all promoter and promoter group entities, explicitly states that "No shares were encumbered during the financial year 2025-26." This declaration covers all members of the promoter and promoter group, including persons acting in concert, ensuring transparency in shareholding patterns.

Current Promoter Holdings

The company provided a comprehensive breakdown of current shareholding among promoters and promoter group entities:

Regulatory Compliance

The annual disclosure fulfills the company's obligation under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Company Secretary Trupti Ranjan Mohanty submitted the filing to both BSE Limited and National Stock Exchange of India Limited, ensuring proper dissemination to all stakeholders.

Corporate Structure

Haleos Labs Limited, headquartered in Hyderabad, operates from its registered office at Plot No. 19-III, Road No. 71, Jubilee Hills. The company trades on stock exchanges under the symbol HALEOSLABS with scrip code 540679 on BSE. The disclosure reinforces the company's commitment to maintaining transparent corporate governance practices and regulatory compliance in its shareholding structure.